ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Zhang, Zhaoyong; Zeng, Eric; Zhang, Lu; Wang, Weiming; Jin, Yingkang; Sun, Jiye; Huang, Shuxiang; Yin, Wenguang; Dai, Jun; Zhuang, Zhen; Chen, Zhao; Sun, Jing; Zhu, Airu; Li, Fang; Cao, Weitao; Li, Xiaobo; Shi, Yongxia; Gan, Mian; Zhang, Shengnan; Wei, Peilan; Huang, Jicheng; Zhong, Nanshan; Zhong, Guocai*; Zhao, Jingxian*; Wang, Yanqun*; Shao, Weihui*; Zhao, Jincun*广州医学院; 1
Cell Discovery2021-8-12DOI: 10.1038/s41421-021-00302-0
40被引4阅读
引用收藏
分享

摘要

The current COVID-19 pandemic, caused by SARS-CoV-2, poses a serious public health threat. Effective therapeutic and prophylactic treatments are urgently needed. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS-CoV-2, which binds to the receptor binding domain (RBD) of SARS-CoV-2 spike protein. Here, we developed recombinant human ACE2-Fc fusion protein (hACE2-Fc) and a hACE2-Fc mutant with reduced catalytic activity. hACE2-Fc and the hACE2-Fc mutant both efficiently blocked entry of SARS-CoV-2, SARS-CoV, and HCoV-NL63 into hACE2-expressing cells and inhibited SARS-CoV-2 S protein-mediated cell-cell fusion. hACE2-Fc also neutralized various SARS-CoV-2 strains with enhanced infectivity including D614G and V367F mutations, as well as the emerging SARS-CoV-2 variants, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.1 (Kappa), and B.1.617.2 (Delta), demonstrating its potent and broad-spectrum antiviral effects. In addition, hACE2-Fc proteins protected HBE from SARS-CoV-2 infection. Unlike RBD-targeting neutralizing antibodies, hACE2-Fc treatment did not induce the development of escape mutants. Furthermore, both prophylactic and therapeutic hACE2-Fc treatments effectively protected mice from SARS-CoV-2 infection, as determined by reduced viral replication, weight loss, histological changes, and inflammation in the lungs. The protection provided by hACE2 showed obvious dose-dependent efficacy in vivo. Pharmacokinetic data indicated that hACE2-Fc has a relative long half-life in vivo compared to soluble ACE2, which makes it an excellent candidate for prophylaxis and therapy for COVID-19 as well as for SARS-CoV and HCoV-NL63 infections.

学科与关键词

关键词
CONVERTING ENZYME 2SPIKE PROTEINSOLUBLE CD4RECEPTORSARSMUTATIONSCOVID-19HISATMERS
相关
加载中…
  • Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
    Lu, Mengjia; Yao, Weitong; Li, Yujun*; Ma, Danting; Zhang, Zhaoyong; Wang, Haimin; Tang, Xiaojuan; Wang, Yanqun; Li, Chao; Cheng, Dechun; Lin, Hua; Yin, Yandong*; Zhao, Jincun*; Zhong, Guocai*Microbiology Spectrum, 2023, 11(4).
  • Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019
    Feng, Long; Fu, Shihui; Zhang, Pei; Zhang, Yujie; Zhao, Yali*; Yao, Yao*; Luo, Leiming*; Ping, Ping*Frontiers in Public Health, 2022, 10: 1050034.
  • Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
    Ge, Jiwan; Wang, Ruoke; Ju, Bin; Zhang, Qi; Sun, Jing; Chen, Peng; Zhang, Senyan; Tian, Yuling; Shan, Sisi; Cheng, Lin; Zhou, Bing; Song, Shuo; Zhao, Juanjuan; Wang, Haiyan; Shi, Xuanling; Ding, Qiang; Liu, Lei; Zhao, Jincun; Zhang, Zheng*; Wang, Xinquan*; Zhang, Linqi*Nature Communications, 2021, 12(1): 250.被引 79
查看全部 →

发表信息

论文状态
公开发表
期刊
Cell Discovery
发表日期
2021-08-12
卷期
第 7 卷, 第 1 期
页码
65
DOI
10.1038/s41421-021-00302-0
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
National Key R&D Program of China [2018YFC1200100, 2018ZX10301403, 2018YFC1311900, 2020YFC0842400]; National Natural Science Foundation of China [82025001]; Ministry of Science and Technology of Guangdong province [2020B1111330001, 2020A111128008, 2020B1111320003, 2020A0505100063, 2020KZDZX1158, B195001248, 2020A1515010911, 2019TX05Y120]; Guangdong Science and Technology Foundation [2019B030316028]; Guangzhou Institute of Respiratory Health Open Project (China Evergrande Group) [2020GIRHHMS07, 2020GIRHHMS24]; State Key Laboratory of Respiratory Disease [SKLRD-QN-201912, SKLRD-Z-202007]; Guangzhou Medical University High-level University Innovation Team Training Program (Guangzhou Medical University) [159]; Ministry of Education of Guangdong province [2020B1111330001, 2020A111128008, 2020B1111320003, 2020A0505100063, 2020KZDZX1158, B195001248, 2020A1515010911, 2019TX05Y120]

作者

  • Z

    Zhang, Zhaoyong (第一作者)

    1 · guangzhou med univ

  • Z

    Zeng, Eric

查看全部 27 位作者收起作者
  • Z

    Zhang, Lu

  • W

    Wang, Weiming

  • J

    Jin, Yingkang

    guangzhou med univ · guangzhou women & childrens med ctr

  • S

    Sun, Jiye

  • H

    Huang, Shuxiang

  • Y

    Yin, Wenguang

    1 · guangzhou med univ

  • D

    Dai, Jun

  • Z

    Zhuang, Zhen

    1 · guangzhou med univ

  • C

    Chen, Zhao

    1 · guangzhou med univ

  • S

    Sun, Jing

    1 · guangzhou med univ

  • Z

    Zhu, Airu

    1 · guangzhou med univ

  • L

    Li, Fang

    1 · guangzhou med univ

  • C

    Cao, Weitao

    1 · guangzhou med univ

  • L

    Li, Xiaobo

  • S

    Shi, Yongxia

  • G

    Gan, Mian

    1 · guangzhou med univ

  • Z

    Zhang, Shengnan

    1 · guangzhou med univ

  • W

    Wei, Peilan

    1 · guangzhou med univ

  • H

    Huang, Jicheng

  • Z

    Zhong, Nanshan

    1 · guangzhou med univ

  • Z

    Zhong, Guocai (通讯)

    peking univ, shenzhen grad sch

  • Z

    Zhao, Jingxian (通讯)

    1 · guangzhou med univ

  • W

    Wang, Yanqun (通讯)

    1 · guangzhou med univ

  • S

    Shao, Weihui (通讯)

  • Z

    Zhao, Jincun (通讯)

    1 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417